Erasca is a clinical-stage precision oncology company driven by a bold mission—to erase cancer by shutting down one of cancer's most commonly mutated pathways.

San Diego, CA
Joined July 2021
Thank you, @LustgartenFDN, for the Hope Through Science Award. We’re proud to support the shared mission of improving outcomes for patients with pancreatic cancer. #PancreaticCancer
1
1
170
RAS mutations drive ~30% of all cancers. Thank you, @stephaniesirota, for the opportunity to discuss Erasca’s journey and our commitment to advancing therapies for patients with RAS/MAPK-driven cancers. #ASCO2026
In our #ASCO2026 coffee break miniseries, RTW CBO @stephaniesirota chatted with Dr. Shannon Morris, Chief Medical Officer of @Erasca. Dr. Morris shared the story behind Erasca's name and what it took to pursue a corner of oncology that was historically considered undruggable. The mic drop moment is when Dr. Morris shares that RAS mutations drive 30% of all tumor types.
211
We’re proud to join Erasca in a strategic research and development collaboration to evaluate multiple agents from their pipeline targeting the RAS/MAPK pathway. Learn more: fal.cn/3rgJV @Erasca @SKopetz @DavidHongMD #EndCancer
6
11
Please join us for the @Erasca Virtual R&D Day on Lead Clinical Programs ERAS-007 & ERAS-601 in Advanced Solid Tumors featuring Dr. David Hong (MD Anderson Cancer Center). A live Q&A session will follow. Register Here: lifesci.events/ERAS2
1
1
Please join us for this exciting event!
Please join us on Tuesday, April 12th at 4:30 PM EDT for the @Erasca Investor Event featuring Scott Kopetz, M.D., Ph.D., (MD Anderson Cancer Center). A live Q&A session will follow. Register here: lifesci.events/ERAS
A big, warm welcome to the @erascainc team! 👏👏👏 Erasca, Inc. joins us in Times Square to ring the @Nasdaq Opening Bell in honor of their IPO. 🎉 #EraseCancer
2
5
3
20
Welcome to the @Nasdaq family, @erascainc! Erasca, Inc. is a clinical-stage precision oncology company driven by a bold mission: to erase cancer by shutting down one of cancer's most commonly mutated pathways. #EraseCancer Now trading: $ERAS
1
3
3
.@erascainc is a clinical-stage precision oncology company driven by a bold mission​—to erase cancer. We speak with CEO Jonathan E. Lim, M.D., about the company’s vision. xitter.cf/i/broadcasts/1YqGoypaX…
1
5
6
Behind the scenes at @Nasdaq
1
2